Hayley Virgil

Senior Editor, OncLive®
Hayley Virgil heads OncLive's feature article efforts and specializes in social issues and equality in oncology. Prior to joining the company in early 2020, she worked as an editor in numerous industries, including media, marketing, hospitality, and computer science, and freelanced in subjects such as history, culture, and the natural sciences.

Articles

Inaugural AACR Cancer Disparities Progress Report Spotlights Growing Concerns Around Racial Disparities

December 24th 2020

The American Association for Cancer Research revealed a comprehensive, first-of-its-kind AACR Cancer Disparities Progress Report, which highlights disparities in cancer incidence, diagnosis, treatment, and survival, along with a heavy emphasis on racial and ethnic disparities in cancer care.

Manochakian Calls for Repeat Genomic Testing Upon Osimertinib Progression in EGFR+ NSCLC

December 20th 2020

Rami Manochakian, MD, discusses the role of osimertinib in patients with EGFR-mutated NSCLC, strategies for treatment following progression on the third-generation TKI, and ongoing research efforts to further improve care.

Immunotherapy Agents Drive Frontline Treatment Strategies in Advanced NSCLC

December 16th 2020

Several immunotherapeutic options are available for non–small cell lung cancer (NSCLC), allowing decisions to be made based on histology, PD-L1 expression, and patient preference in regard to their treatment goals. Looking ahead, there may also be efficacy in moving immunotherapy drugs up into the resectable, early-stage setting

PARP Inhibitors Pave the Way to Cure in Ovarian Cancer

December 14th 2020

Following the results of the SOLO-1 trial, maintenance PARP inhibitors have become the standard of care for patients with BRCA-mutated ovarian cancer but overall survival data are needed to confirm their potentially curative benefit.

Tucatinib Triplet Prolongs Time to Deterioration of HRQOL in HER2+ Breast Cancer With Brain Metastases

December 12th 2020

December 11, 2020 - Tucatinib in combination with trastuzumab and capecitabine significantly prolonged the time to deterioration of health-related quality of life in patients with HER2- positive metastatic breast cancer with brain metastases.

Neoadjuvant Atezolizumab/Chemo Improves Outcomes Without Impacting Day-to-Day Function or HRQoL in Early TNBC

December 10th 2020

December 10, 2020 - The addition of neoadjuvant atezolizumab to nab-paclitaxel followed by doxorubicin plus cyclophosphamide was found to improve pathologic complete responses compared with placebo plus chemotherapy in patients with early triple-negative breast cancer without adding additional treatment burden to patients.

AI-Digital Breast Cancer Risk Assessment Platform Accurately Classifies Low-Risk Recurrence Scores

December 9th 2020

December 9, 2020 - The artificial intelligence–digital breast cancer risk discrimination platform PreciseDx was able to classify patients with Oncotype Dx low-risk recurrence scores with high accuracy using only hematoxylin and eosin stain images and limited clinical data.

Trilaciclib Prior to Myelosuppressive Chemo Reduces Need for Supportive Care in Small Cell Lung Cancer

December 9th 2020

Renata Ferrarotto, MD, discusses trilaciclib’s unique mechanism of action in small cell lung cancer and the data that led to its FDA designation.

BCMA-Targeted ADC MEDI2228 Induces Deep Responses in Heavily Pretreated Myeloma

December 9th 2020

December 9, 2020 — The BCMA-targeted antibody-drug conjugate MEDI2228 showed promising clinical efficacy in patients with relapsed/refractory multiple myeloma, with triple-refractory disease experiencing maintained responses.

Standardized Practices Address Challenges With Germline Genetic Testing in Prostate Cancer

December 8th 2020

December 8, 2020 — Although updated guidelines and targeted therapies have led to the routine recommendation of germline genetic testing for patients with prostate cancer, increasing demand for tests and limited access to genetics providers have created an unmet need.

Pooled Analysis of 4 Clinical Trials Reflects Low Cardiac Risk With Acalabrutinib in CLL

December 8th 2020

Patients with chronic lymphocytic leukemia who received treatment with single-agent acalabrutinib experienced a low incidence of cardiac toxicities leading to treatment discontinuation.

Survival Following Post–HCT Relapse in ALL Improves With Targeted Immunotherapies

December 7th 2020

December 7, 2020 - Survival rates of adult patients with acute lymphoblastic leukemia who experience relapse following hematopoietic cell transplantation has considerably improved within the past few years, possibly due to the increased use of immunotherapy agents.

Fruquintinib Enters Phase 3 Trial for Metastatic Colorectal Cancer

December 7th 2020

December 7, 2020 - The survival benefit of the novel agent fruquintinib will be tested during the phase 3 FRESCO-2 trial in patients with metastatic colorectal cancer who are either intolerant to or have received 3 prior lines of chemotherapy.

African-American Race: An Independent Predictor of Poor Survival in Younger Patients With AML?

December 7th 2020

December 6, 2020 - Self-reported black race was found to be the most important factor associated with poor survival in patients under 60 years old with acute myeloid leukemia.

BCMA/CD3 Bispecific Antibody REGN5458 Elicits Early, Deep Responses in Relapsed/Refractory Myeloma

December 6th 2020

December 6, 2020 — REGN5458, a BCMA- and CD3-targeted bispecific monoclonal antibody, demonstrated early, deep, and durable responses with acceptable safety and tolerability in patients with relapsed/refractory multiple myeloma.

GTB-3550 TriKE Stimulates Natural Killer Cell Function in MDS and AML

December 6th 2020

December 5, 2020 - GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia.

Oxidative Stress, Antioxidant Status Remain High in Nigerian Patients With Prostate Cancer

December 4th 2020

Nigerian patients with prostate cancer are noted as having higher levels of total plasma peroxide, malondialdehyde, and nitric oxide, as well as lower levels of total antioxidant capacity, even while undergoing androgen-deprivation therapy compared with Nigerian men who don't have prostate cancer.

Next-Generation CD47 Blocker ALX148/Azacitidine Combo Under Exploration in MDS

December 4th 2020

December 4, 2020 - The first patient with higher-risk myelodysplastic syndrome has been dosed with a novel combination comprised of the next-generation CD47 blocker ALX148 plus azacitidine as part of the phase 1/2 ASPEN-02 study, the first of several planned studies to examine the agent in those with myeloid malignancies.

Phase 2 Trial Expanded to Examine AGEN1181 Plus Balstilimab in Colon Cancer

December 3rd 2020

December 3, 2020 - A phase 2 trial has expanded to examine the use of the CTLA-4 antibody AGEN1181 in combination with the novel anti–PD-1 human monoclonal antibody balstilimab in patients with colon cancer.

Pelvic, Abdominal Radiation in Pediatric Patients May Lead to Impaired Metabolic Health as Adults

December 3rd 2020

The use of abdominal or pelvic radiotherapy in pediatric patients with cancer could lead to long-term negative impact on cardiovascular and metabolic health.